Ph-negative acute lymphoblastic leukemia

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Myeloablative allogeneic HCT was associated with dramatically higher non-relapse mortality compared to pediatric-style chemotherapy, with 5-year NRM of 29% vs 8%.

Effect: adverse; HR 5.41 (HCT vs chemotherapy); CI: 95% CI 3.23–9.06

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89

Obesity was independently associated with inferior OS, inferior DFS, increased relapse, and increased NRM in AYAs with Ph-negative ALL, regardless of whether they received chemotherapy or HCT.

Effect: decline; HR 2.17 (obese vs non-obese, OS); CI: 95% CI 1.63–2.89